CLOSED
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is based in Hyderabad, India. Track SAI LIFE SCIENCES LIMITED's live NSE:SAILIFE share price ₹1,342.00 (+2.05%), market cap ₹₹285B, P/E 81.6. MarketRipple's AI analysis covers the investment thesis, ripple-chain impact, and Healthcare sector outlook for SAILIFE — real-time NSE India stock intelligence.
Open
₹1,325.00
High
₹1,350.00
Low
₹1,315.20
Prev. Close
₹1,315.00
52W High
₹1,320.70
52W Low
₹778.50
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is based in Hyderabad, India.
Key Takeaway
SAI LIFE SCIENCES LIMITED is rated strong buy with a P/E of 81.6x — understand the valuation context before sizing a position.
★ Recommended
Ask AI: Is SAI LIFE SCIENCES LIMITED fairly valued right now?
Because a P/E of 81.6x needs to be compared against sector peers and growth expectations to be meaningful.
Continue Research
View events affecting SAI LIFE SCIENCES LIMITED
Because the investment case must account for macro and company-specific developments — events reveal the 'why' behind price moves.
Trace sector ripple effects
Because Healthcare moves create upstream and downstream implications that affect the entire thesis.
Intelligence Path
Growth
Govt Exposure
Policy Dependence
Execution Quality
News Sensitivity
Debt Strength
602 Cr
Revenue
104 Cr
Net Profit
15.1%
ROE
0%
ROCE
16.44
EPS
| ₹ in Crore | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|
| Revenue | 1,197 | 1,456 | 1,695 | 2,192 | 2,234 |
| Net Profit | 10 | 83 | 170 | 349 | 352 |
| ROE (%) | — | — | — | 15.1% | 15.1% |
| EPS (₹) | — | — | — | 16.44 | 16.44 |
| Debt/Equity | — | — | — | 11.6 | 11.6 |